"Hallucinogens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
| Descriptor ID |
D006213
|
| MeSH Number(s) |
D27.505.696.388 D27.505.954.427.700.372
|
| Concept/Terms |
Hallucinogens- Hallucinogens
- Psychotomimetic Agents
- Agents, Psychotomimetic
- Hallucinogenic Agents
- Agents, Hallucinogenic
- Hallucinogenic Substances
- Substances, Hallucinogenic
- Psychedelics
- Psychedelic Agents
- Agents, Psychedelic
- Hallucinogenic Drugs
- Drugs, Hallucinogenic
|
Below are MeSH descriptors whose meaning is more general than "Hallucinogens".
Below are MeSH descriptors whose meaning is more specific than "Hallucinogens".
This graph shows the total number of publications written about "Hallucinogens" by people in this website by year, and whether "Hallucinogens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 2 | 1 | 3 |
| 2009 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hallucinogens" by people in Profiles.
-
Averill LA, Abdallah CG. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs. 2022 02; 31(2):133-137.
-
Louie AK, Beresin EV, Coverdale J, Balon R, Guerrero APS, Morreale MK, Aggarwal R, Brenner AM. Are Psychedelics Something New in Teaching Psychopharmacology? Acad Psychiatry. 2020 Oct; 44(5):511-514.
-
Deng H, Verrico CD, Kosten TR, Nielsen DA. Psychosis and synthetic cannabinoids. Psychiatry Res. 2018 10; 268:400-412.
-
Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018 09; 43(10):2154-2160.
-
Storch EA, Kay BC. Commentary on Spradlin et al.: Is marijuana use common in OCD? Addict Behav. 2019 06; 93:267-268.
-
Brodrick J, Mitchell BG. Hallucinogen Persisting Perception Disorder and Risk of Suicide. J Pharm Pract. 2016 Aug; 29(4):431-4.
-
Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen HH, Sanchez LA. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol. 2014 Mar; 35(1):20-5.
-
Atkins K, Burks T, Swann AC, Dafny N. MDMA (ecstasy) modulates locomotor and prefrontal cortex sensory evoked activity. Brain Res. 2009 Dec 11; 1302:175-82.
-
Wan L, Baldridge RM, Colby AM, Stanford MS. Enhanced intensity dependence and aggression history indicate previous regular ecstasy use in abstinent polydrug users. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13; 33(8):1484-90.
-
Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82.